Increasing
the odds
Giving everyone diagnosed with cancer, their best chance to become cancer free.
56%
Studies in upper gastrointestinal cancer have shown that up to 56% of patients¹ with early stage disease have previously undetected cancer cells in lymph nodes.
This can lead to inaccurate diagnosis and disease recurrence. Ferronova has developed a surgical oncology tracer system that aims to improve the treatment guidance and staging of complex cancers and help increase survival rates.
The gap
More than 40% of people will be diagnosed with cancer during their lifetime. Successful cancer treatment relies on accurate therapies to remove or treat lymph nodes at high risk of containing cancer. Current technologies and methods sometimes leave behind lymph nodes with cancer cells and are not able to reliably detect small tumours in removed lymph nodes.
Our solution
Our unique IP technology is a new-generation, polymer-coated magnetic nanoparticle.
This nanoparticle is detected on MRI for radiotherapy and surgical planning. It also drives a magnetically guided detection system designed to precisely identify sentinel lymph nodes, to assist surgeons and pathologists to more accurately stage solid tumours and locate and address micro-metastases that may otherwise go undetected.
The future of cancer
imaging and surgery
Generate a clear roadmap of the lymphatic system for precise surgical lymph node resection and radiation planning
Facilitate accurate identification of true sentinel nodes for pathology ultra-staging
Enable detection of micro-metastases that would otherwise be missed
Gastrointestinal cancers
The magnetic technology is well suited to complex cancers like colorectal and upper GI cancers, where resolution and the ability to locate sentinel lymph nodes close to the injection site are critical.
Our roadmap
May 2016
2020-2023
2024+
Ferronova Incorporated
First In-human and Feasibility Trials
Pivotal Trials
Our roadmap
May 2016
Ferronova Incorporated
2020-2023
First In-human and Feasibility Trials
2024+
Pivotal Trials
Clinical trials
Ferronova has completed a 15 patient first in-human trial and has multiple trials in progress.
1. Matsumoto, M., Natsugoe, S., Nakashima, S., Sakamoto, F., Okumura, H., Sakita, H., Baba, M., Takao, S. and Aikou, T., 2000. Clinical significance of lymph node micrometastasis of pN0 esophageal squamous cell carcinoma. Cancer letters, 153(1-2), pp.189-197